Financial results for the period ended September 30, 2026
As filed · Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
EarningsMajormateriality 78 out of 100
What happened
FactFinancial results for the period ended September 30, 2026. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review. Rs.7.00 (Rupees seven only) per equity share of Re.1/- each.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27. (management committed by Q1 FY27)
Evidence
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%